PEEL-224 is under clinical development by Peel Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PEEL-224’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PEEL-224 is under development for the treatment of advanced solid tumor, Ewing sarcoma, neuroblastoma, and rhabdomyosarcoma in children. The drug candidate is a prodrug comprises of engineered SN22 (7-Ethylcamptothecin) reversibly linked to biocompatible nanocarrier molecules. It is a administered through intravenous route.
Peel Therapeutics overview
Peel Therapeutics is a biotechnology company that discovers and develops medicines for the treatment of cancer and inflammatory diseases. It is investigating PEEL-224, a chemotherapeutic nanoparticle targeting cancer; and EP53 lipid nanoparticles against other oncology indications. The company is also evaluating neutrophil targeting peptides (NTP) to treat COVID-19, inflammatory diseases and immune-triggered thrombosis. Peel Therapeutics develops its pipeline from the assets inspired by the evolution of elephants, plants, and humans. It works in collaboration with the University of Utah and ARUP Laboratory. The company operates in the US and Israel. Peel Therapeutics is headquartered in Salt Lake City, Utah, the US.
For a complete picture of PEEL-224’s drug-specific PTSR and LoA scores, buy the report here.